<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>5(9)</volume><submitter>Gattelli A</submitter><pubmed_abstract>We show that elevated levels of Ret receptor are found in different sub-types of human breast cancers and that high Ret correlates with decreased metastasis-free survival. The role of Ret in ER+ breast cancer models was explored combining in vitro and in vivo approaches. Our analyses revealed that ligand-induced Ret activation: (i) stimulates migration of breast cancer cells; (ii) rescues cells from anti-proliferative effects of endocrine treatment and (iii) stimulates expression of cytokines in the presence of endocrine agents. Indeed, we uncovered a positive feed-forward loop between the inflammatory cytokine IL6 and Ret that links them at the expression and the functional level. In vivo inhibition of Ret in a metastatic breast cancer model inhibits tumour outgrowth and metastatic potential. Ret inhibition blocks the feed-forward loop by down-regulating Ret levels, as well as decreasing activity of Fak, an integrator of IL6-Ret signalling. Our results suggest that Ret kinase should be considered as a novel therapeutic target in subsets of breast cancer.</pubmed_abstract><journal>EMBO molecular medicine</journal><pagination>1335-50</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3799490</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.</pubmed_title><pmcid>PMC3799490</pmcid><pubmed_authors>Lienhard S</pubmed_authors><pubmed_authors>Kenner L</pubmed_authors><pubmed_authors>Torres-Arzayus MI</pubmed_authors><pubmed_authors>Hynes NE</pubmed_authors><pubmed_authors>Boulay A</pubmed_authors><pubmed_authors>Nalvarte I</pubmed_authors><pubmed_authors>Schreiber M</pubmed_authors><pubmed_authors>Carragher N</pubmed_authors><pubmed_authors>Schlederer M</pubmed_authors><pubmed_authors>Gattelli A</pubmed_authors><pubmed_authors>Roloff TC</pubmed_authors><pubmed_authors>Macleod KK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells.</name><description>We show that elevated levels of Ret receptor are found in different sub-types of human breast cancers and that high Ret correlates with decreased metastasis-free survival. The role of Ret in ER+ breast cancer models was explored combining in vitro and in vivo approaches. Our analyses revealed that ligand-induced Ret activation: (i) stimulates migration of breast cancer cells; (ii) rescues cells from anti-proliferative effects of endocrine treatment and (iii) stimulates expression of cytokines in the presence of endocrine agents. Indeed, we uncovered a positive feed-forward loop between the inflammatory cytokine IL6 and Ret that links them at the expression and the functional level. In vivo inhibition of Ret in a metastatic breast cancer model inhibits tumour outgrowth and metastatic potential. Ret inhibition blocks the feed-forward loop by down-regulating Ret levels, as well as decreasing activity of Fak, an integrator of IL6-Ret signalling. Our results suggest that Ret kinase should be considered as a novel therapeutic target in subsets of breast cancer.</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013 Sep</publication><modification>2021-02-20T04:03:04Z</modification><creation>2019-03-27T01:17:18Z</creation></dates><accession>S-EPMC3799490</accession><cross_references><pubmed>23868506</pubmed><doi>10.1002/emmm.201302625</doi></cross_references></HashMap>